Three Year Follow-Up Results Confirm Efficacy of StemSpine® Procedure for Treating Chronic Lower Back Pain, with No Serious Adverse Effects

Rhea-AI Summary

Creative Medical Technology Holdings (NASDAQ: CELZ) announced positive three-year follow-up data from its StemSpine® pilot study, showing continued efficacy for treating chronic lower back pain. The study, which utilizes a patient's own bone marrow aspirate, reported an 87% efficacy rate with no serious adverse effects. Notably, no patients required re-dosage or surgical intervention since the last follow-up. The patent also covers the use of allogenic cells, expanding treatment options for millions suffering from chronic pain. CEO Timothy Warbington emphasized the procedure's potential to repair and improve blood supply around the disc.

Positive

• 87% efficacy rate reported in chronic lower back pain treatment.
• No serious adverse effects were observed over three years.
• No patients needed re-dosage or additional surgical intervention.

Negative

• None.

PHOENIX--(BUSINESS WIRE)-- Creative Medical Technology Holdings, Inc. ("Creative Medical Technology Holdings" or the "Company") (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced positive three-year follow-up data for the Company's StemSpine® pilot study. The three-year data demonstrates continued efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.

StemSpine® is a patented procedure that primarily utilizes a patient's own bone marrow aspirate for the treatment of chronic lower back pain. The issued patent also covers the use of allogenic (donor) cells for this condition, which provides the Company with additional options for treating millions of potential patients suffering from chronic lower back pain.

There were no safety related concerns at up to three years, and the StemSpine® procedure resulted in a continued efficacy rate of 87% of patients that participated in the pilot study. No patients required re-dosage or surgical intervention since the last follow-up at two years.

"To our knowledge, this pilot is the first demonstration of the clinical efficacy of injecting bone marrow aspirate in areas surrounding the disc, thereby potentially repairing, remodeling and improving the blood supply around the disc and lower back area. We believe StemSpine® represents an attractive potential option for millions of Americans who suffer from non-surgical chronic lower back pain," said Timothy Warbington, President and CEO of the Company.

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics and is traded on NASDAQ under the ticker symbol CELZ. For further information about the Company, please visit www.creativemedicaltechnology.com.

Special Note Regarding Forward Looking Statements

NASDAQ Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230213005676/en/

Company Contact

Creative Medical Technology

IR@CreativeMedicalTechnology.com

Investor Relations

Devin Sullivan, Managing Director

The Equity Group Inc.

dsullivan@equityny.com

David Shayne, Analyst

dshayne@equityny.com

Source: Creative Medical Technology Holdings, Inc.

FAQ

What are the results from the three-year follow-up study of StemSpine® by Creative Medical Technology Holdings?

The study reported an 87% efficacy rate in treating chronic lower back pain with no serious adverse effects.

What does the StemSpine® procedure utilize in its treatment?

The StemSpine® procedure primarily uses a patient's own bone marrow aspirate.

Was there any need for additional surgical intervention in the StemSpine® study participants?

No patients required re-dosage or surgical intervention since the last follow-up at two years.

What does the patent for StemSpine® cover?

The patent covers the use of a patient's own bone marrow and allogenic (donor) cells for treating chronic lower back pain.

How does StemSpine® aim to help chronic lower back pain sufferers?

It potentially repairs and improves blood supply around the disc and lower back area.